Mirati Therapeutics, Inc. (MRTX) SVP Jamie Christensen Sells 7,499 Shares
Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $14.00, for a total value of $104,986.00. Following the completion of the transaction, the senior vice president now owns 10,169 shares of the company’s stock, valued at $142,366. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Jamie Christensen also recently made the following trade(s):
- On Wednesday, October 4th, Jamie Christensen sold 4,000 shares of Mirati Therapeutics stock. The stock was sold at an average price of $14.00, for a total value of $56,000.00.
- On Friday, September 15th, Jamie Christensen sold 770 shares of Mirati Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $9,240.00.
Mirati Therapeutics, Inc. (NASDAQ:MRTX) traded up $1.35 on Friday, hitting $14.05. The stock had a trading volume of 345,076 shares, compared to its average volume of 428,133.
Mirati Therapeutics (NASDAQ:MRTX) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.16. analysts expect that Mirati Therapeutics, Inc. will post -3.21 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Mirati Therapeutics, Inc. (MRTX) SVP Jamie Christensen Sells 7,499 Shares” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/11/03/mirati-therapeutics-inc-mrtx-svp-jamie-christensen-sells-7499-shares.html.
Several institutional investors and hedge funds have recently bought and sold shares of MRTX. KCG Holdings Inc. purchased a new position in shares of Mirati Therapeutics in the 1st quarter worth about $106,000. Susquehanna International Group LLP lifted its stake in shares of Mirati Therapeutics by 46.5% in the 2nd quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 16,030 shares during the last quarter. PDT Partners LLC bought a new stake in shares of Mirati Therapeutics in the 2nd quarter valued at about $200,000. LMR Partners LLP bought a new stake in shares of Mirati Therapeutics in the 2nd quarter valued at about $236,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Mirati Therapeutics by 22.9% in the 1st quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock valued at $328,000 after acquiring an additional 11,753 shares during the last quarter. Hedge funds and other institutional investors own 59.95% of the company’s stock.
Several equities analysts recently commented on the company. Jefferies Group LLC set a $5.00 target price on Mirati Therapeutics and gave the stock a “hold” rating in a research report on Friday, August 4th. ValuEngine cut Mirati Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 7th. SunTrust Banks, Inc. restated a “buy” rating and set a $13.00 target price on shares of Mirati Therapeutics in a research report on Monday, October 2nd. CIBC assumed coverage on Mirati Therapeutics in a research report on Tuesday, September 19th. They set an “outperform” rating and a $18.00 target price for the company. Finally, Cann assumed coverage on Mirati Therapeutics in a research report on Tuesday, September 19th. They set an “outperform” rating for the company. Two analysts have rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $13.88.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.